+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Selexipag"

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report by Drug Class, Type (Branded, Generics), Route of Administration (Oral, Intravenous/Subcutaneous, Inhalational) and Region with Growth Forecasts, 2025-2033 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report by Drug Class, Type (Branded, Generics), Route of Administration (Oral, Intravenous/Subcutaneous, Inhalational) and Region with Growth Forecasts, 2025-2033

  • Report
  • November 2025
  • 150 Pages
  • Global
From
Calcium Channel Blocker Market Report 2025 - Product Thumbnail Image

Calcium Channel Blocker Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Pulmonary Hypertension - Pipeline Insight, 2025 - Product Thumbnail Image

Pulmonary Hypertension - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Cardiovascular Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Thumbnail Image

Cardiovascular Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • May 2025
  • 118 Pages
  • Global
From
Hypertension Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Hypertension Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Pulmonary Hypertension Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Thumbnail Image

Pulmonary Hypertension Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • September 2025
  • 124 Pages
  • Global
From
Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029) - Product Thumbnail Image

Branded PAH Therapeutics Market (2023 Edition) - Analysis By Drug Class, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

  • Report
  • November 2023
  • 250 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • January 2024
  • 250 Pages
  • Global
From
North America Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel - Product Thumbnail Image

North America Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel

  • Report
  • February 2023
  • 143 Pages
  • North America
From
South & Central America Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel - Product Thumbnail Image

South & Central America Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Drugs, Type, Route of Administration, and Distribution Channel

  • Report
  • February 2023
  • 128 Pages
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Selexipag is a drug used to treat pulmonary arterial hypertension (PAH), a type of cardiovascular disease. It is a selective prostacyclin receptor agonist, meaning it works by stimulating the prostacyclin receptor to reduce the pressure in the pulmonary arteries. Selexipag is taken orally and is available in tablet form. It is typically prescribed in combination with other drugs to treat PAH. Selexipag is approved for use in the United States, Europe, and other countries. It is marketed by Actelion Pharmaceuticals, a subsidiary of Johnson & Johnson, and is available in several countries. Other companies that produce and market selexipag include United Therapeutics Corporation, GlaxoSmithKline, and Bayer AG. Show Less Read more